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a  b  s  t  r  a  c  t
Background:  Although  angiotensin  receptor  blockers  (ARBs)  are  now  one  of  the  ﬁrst-line  drug  classes
for  the  management  of  hypertension,  recommendations  for the  management  of chronic  heart  failure
(CHF)  are  limited.  The  supplemental  beneﬁt  of  angiotensin  receptor  blocker  in  hypertensive  patients  with
stable heart  failure  using  olmesartan  (SUPPORT)  trial  investigates  whether  an  additive  treatment  with
an ARB,  olmesartan,  reduces  the  mortality  and  morbidity  in  hypertensive  patients  with  stable  chronic
heart  failure.
Methods  and  results:  The  SUPPORT  trial  is a  prospective  randomized  open-label  blinded  endpoint  study.
Between  October  2006  and  March  2010,  1147  stable  CHF  patients  treated  with  evidence-based  medica-
tions  were  successfully  randomized  to  either  olmesartan  or control  group.  In the  olmesartan  group,  thelmesartan ARB  was  initiated  at the dose  of  5.0–10  mg,  and  was then  increased  up  to 40  mg/day,  when  possible.  No
ARBs  were  allowed  in the  control  group.  Primary  outcome  measure  in  the  SUPPORT  trial  is  the  composite
of  all-cause  death,  non-fatal  acute  myocardial  infarction,  non-fatal  stroke  and  hospital  admission  due  to
worsening  heart  failure.  The  participants  will  be followed  for at  least  3 years  until March  2013.
Conclusions:  The  SUPPORT  trial will  elucidate  the  supplemental  beneﬁts  of  an  ARB,  olmesartan,  in  hyper-
tensive  patients  with  CHF.
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In patients with heart failure (HF), inhibition of the
enin–angiotensin–aldosterone system (RAAS) is generally
ecommended to improve mortality and morbidity [1,2]. Although
everal RAAS inhibitors, including angiotensin-converting enzyme
ACE) inhibitors, angiotensin receptor blockers (ARBs), and aldos-
erone blockers, are currently available in the clinical setting, ACE
nhibitors are recommended as the ﬁrst choice for the inhibition
f RAAS in patients with stable HF based on the large body of
 Trial registration: This study is registered at ClinicalTrials.gov – NCT00417222.
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evidence for their beneﬁcial prognostic effects in patients with HF
[1,2]. ARBs could be considered as a reasonable alternative to ACE
inhibitors since they have been shown to improve outcomes in
patients with HF and reduced ejection fraction (HFrEF) who were
intolerant of ACE inhibitors [3,4], as well as in those who have
already been treated with ACE inhibitors [4–6]. However, it is still
controversial whether the supplemental use of an ARB provides
beneﬁcial impacts in hypertensive patients with HF treated with
conventional therapies, particularly in Japan.
Olmesartan is an ARB with strong blood pressure lowering
effects [7] and unique properties to reduce plasma angiotensin II
(Ang II) levels [8–11] and to act as a strong inverse agonist for
angiotensin type I (AT1) receptors [12,13]. In the supplemental
beneﬁt of angiotensin receptor blocker in hypertensive patients
with stable heart failure using olmesartan (SUPPORT) trial, we
thus aimed to test our hypothesis that an additive treatment
with olmesartan reduces the mortality and morbidity of hyper-
tensive patients with stable HF who are treated with conventional
therapies.
vier Ltd. All rights reserved.




































Fig. 1. Study protocol of the SUPPORT trial. A total of 1147 hypertensive patients
stroke, and hospital admission due to worsening heart failure. Sec-2 Y. Sakata et al. / Journal 
ethods
tudy design and objective
The SUPPORT trial is a prospective randomized open-label
linded endpoint (PROBE) study. The objective of the study is to
nvestigate whether additive treatment with an ARB, olmesartan,
educes the mortality and morbidity of hypertensive patients with
table HF. The study has been conducted according to the ethical
rinciples described in the Declaration of Helsinki.
tudy population and sample size
The inclusion and exclusion criteria are listed in Table 1. The
nclusion criteria were designed to enroll stable patients with HF
igns and symptoms and treated with evidence-based conventional
herapies. The exclusion criteria were designed to exclude patients
ith substantive confounding medical conditions or an inability to
eaningfully participate in the SUPPORT trial. Based on the results
rom our preceding CHART-1 study [14,15], we assumed that the
ncidence of the primary composite endpoints employed in the
UPPORT trial would be ∼12% per year and thus 480 patients on
he condition of 3-year follow-up would be required for each arm
o provide 80% power to detect 30% risk reduction by olmesartan,
sing a 2-sided signiﬁcance level of 0.05 by the log-rank test. After
onsidering a maximum 15% for the loss to follow-up or unsuit-
ble for analysis, we calculated that more than 565 patients in each
roup (control and olmesartan) would be needed to complete the
rial.
tudy protocol
Patient randomization was performed according to a 1:1 ratio of
lmesartan to control, through stratiﬁcation by participating insti-
ute, sex, and age (Fig. 1). In the olmesartan group, the ARB was
nitiated at the dose of 5–10 mg,  and then physicians were encour-
ged to increase the dose up to 40 mg/day, when possible. No ARBs
ere allowed in the control group. All the patients will be fol-owed up for at least 3 years until March 2013. All physicians are
ncouraged to control blood pressure of the patients in each group
ccording to the recommendations in the JNC7 [16].
able 1
nclusion and exclusion criteria.
Inclusion criteria:
• Patients with New York Heart Association class II through IV chronic
heart failure
•  Patients who have a history of hypertension or those who are treated
with antihypertensive medications
• Patients who are aged 20 years or older and less than 80 years at the entry
•  Stable patients who  have angiotensin-converting enzyme inhibitor
and/or -blocker
• Patients who are not treated with angiotensin II receptor blocker
Exclusion criteria:
• Patients who have renal dysfunction (serum creatinine ≥ 3.0 mg/dL) or
those who are under chronic hemodialysis
•  Drug hypersensitivity to olmesartan
• Severe liver dysfunction
•  History of angioedema
• Malignant tumor or life-threatening illness of poor prognosis
•  Pregnant or possibly pregnant patients
• Cardiovascular surgery within 6 months prior to the date of the entry
•  Acute myocardial infarction within 6 months prior to the date of the
entry
•  Percutaneous coronary intervention with or without stent implantation
within 6 months prior to the date of the entry
ther patients deemed unsuitable as subjects of the study by treating physician.with stable heart failure were successfully randomized into either the olmesartan
or  the control group. ARB, angiotensin receptor blocker.
In addition to the prognostic effects of olmesartan in patients
with stable HF patients, the SUPPORT trial was  designed to address
its possible beneﬁcial effects on metabolic markers, including
serum levels of high sensitive C-reactive peptide, adiponectin
[1–20], and several microRNAs [21,22], as well as each component
of metabolic syndrome.
Study endpoints and data analysis
The primary and secondary outcome measures are listed in
Table 2. Brieﬂy, the primary endpoint is the composite endpoints
of all-cause death, non-fatal acute myocardial infarction, non-fatalondary endpoints consist of the modes of death, worsening HF,
surrogate markers for HF and development of cardiovascular dis-
ease, atrial ﬁbrillation, diabetes, and renal failure. The primary
Table 2
Primary and secondary outcome measures.
Primary outcome measures:
A composite of the following outcomes
• All-cause death
• Non-fatal acute myocardial infarction
•  Non-fatal stroke
• Hospital admission due to worsening heart failure
Secondary outcome measures:
•  Cardiovascular death
•  Death due to heart failure
• Sudden death
•  Acute myocardial infarction
• Stroke
• Hospital admission from any cardiovascular reasons
•  Fatal arrhythmia or appropriate ICD discharge
•  Newly diagnosed diabetes
• Development of renal failure
• New-onset atrial ﬁbrillation
• A need to modify treatment procedures for heart failure
•  A decrease in left ventricular ejection fraction
• An increase in B-type natriuretic peptide levels (≥2-fold increase if the
baseline level was  ≥50 pg/ml and an increase to 100 pg/ml if the baseline
level was  <50 pg/ml)
• Changes in serum markers for metabolic syndrome (high sensitivity
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nd secondary endpoints will be analyzed based on the time
o the ﬁrst occurrence. Survival curves will be estimated using
he Kaplan–Meier procedure and compared with a 2-sided log-
ank test. The effects of olmesartan will be examined using Cox
roportional hazards models. In addition, subgroup analysis will
e performed according to gender, EF, and other parameters, if
eeded.
tudy organization
The Executive Committee consists of a principal investigator and
ore members from the participating institutions and is responsible
or the development of the study protocol and oversees the progress
omprehensively. The Executive Committee also functions as the
ublication Committee for this trial. A Steering Committee provides
uidance on the logistics of the study. The Endpoint Evaluation
ommittee consists of 2 cardiologists and a neurologist, reviews
linical events, and adjudicates primary endpoints. The Data Safety
onitoring Board is independent of the study committees and pro-
ides the Steering Committee with advice when there exists any
oncern about participants’ safety. The Statistical Analysis Board
ill perform statistical analyses independently from all of the com-
ittees.
tatus of the study
The SUPPORT trial was registered at ClinicalTrials.gov
http://www.clinicaltrials.gov/) with the identiﬁer NCT00417222,
nd received Ethics Committee approval before initiation in each
nstitution. Written informed consent was obtained from every
ubject before trial participation. Between October 2006 and
arch 2010, a total of 1147 patients were successfully enrolled
rom the 24 participating hospitals of the Chronic Heart Failure
nalysis and Registry in the Tohoku District 2 (CHART-2) Study
NCT00418041) [23,24] (Table 3), and were successfully allocated
andomly to either the olmesartan group (N = 578) or the control




Age (years) 65.7 ± 10.2
BMI  (kg/m2) 24.5 ± 3.9
Systolic BP (mmHg) 127.9 ± 18
Diastolic BP (mmHg) 74.3 ± 11.7
Heart rate (bpm) 71.4 ± 14.2
LVEF (%) 54.1 ± 14.7




Cerebrovascular disease 168 (15%)
Cancer 89 (8%)
Ischemic heart disease 535 (47%)
Dilated cardiomyopathy 243 (21%)
Hypertrophic cardiomyopathy 37 (3%)
Valvular heart disease 215 (19%)
Hypertensive heart disease 139 (12%)
Medication
Beta blockers 813 (71%)
ACE inhibitors 923 (80%)
Diuretics 648 (56%)
Calcium channel blockers 440 (38%)
Statins 548 (48%)
umerical data are expressed as mean ± SD. BMI, body mass index; BP, blood pres-
ure; LVEF, left ventricular ejection fraction; ACE, angiotensin-converting enzyme.iology 62 (2013) 31–36 33
Discussion
ARBs for the management of hypertensive patients with HF
Inhibition of the RAAS is widely recommended as one of the
ﬁrst-line treatments for chronic HF [1,2]. Besides lowering blood
pressure, ARBs promote regression of left ventricular hypertrophy
and improve morbidity and mortality in patients with hypertension
and other cardiovascular diseases. However, few previous trials
evaluated the effects of an ARB in hypertensive patients with HF,
although ARBs generally appear to provide beneﬁts in hyperten-
sive patients without HF but at high risk for cardiovascular events
(Table 3). In addition, it is still controversial whether the supple-
mental use of ARBs may  provide beneﬁcial impacts in HF patients
treated with conventional therapies [4–6,25,26]. Thus, in the SUP-
PORT trial, we aimed to investigate the beneﬁcial impacts of an
ARB, olmesartan, in Japanese hypertensive patients with stable HF
(Table 4).
ARBs for metabolic disorder in hypertensive patients with HF
Metabolic syndrome comprises a cluster of abdominal obe-
sity, dyslipidemia, elevated blood pressure, and insulin resistance.
Patients with metabolic syndrome have manifestations that occur
in sequence, called the metabolic domino. Because activation of the
renin–angiotensin system (RAS) is involved in this domino effect,
RAS blockade by ARB will offer a therapeutic tool by improving
metabolic disorder as well as by lowering blood pressure. Thus, in
the SUPPORT trial, we sought to investigate the effect of olmesar-
tan, an ARB, on improvement of metabolic parameters with special
reference to changes in several serum markers (Table 2) [17–22].
ARBs for HF with preserved ejection fraction
Although it has been unclear which type of medications could
improve mortality and morbidity in patients with preserved ejec-
tion fraction (HFpEF), a recent report from the Swedish Heart
Failure Registry suggested a beneﬁcial effect of RAS inhibitors on
prognosis in patients with HFpEF [27]. In addition, a post hoc analy-
sis of I-Preserve trial revealed that use of irbesartan was associated
with improved outcomes in HFpEF patients with relatively low
levels of N-terminal proB-type natriuretic peptide (NT-proBNP)
(≤339 pg/mL), suggesting the effects of ARB on early, but not later,
stages of HFpEF [28].
In the SUPPORT trial, we have enrolled a considerable num-
ber of HFpEF patients with various disease backgrounds (Table 3).
Thus, we  will examine the clinical impact of olmesartan in patients
with HFpEF in relation to several clinical parameters including
NT-proBNP.
ACE inhibitory action of olmesartan
In order to explore the clinical potential of ARBs in hypertensive
patients with HF, we employed olmesartan in the SUPPORT trial
since it has several unique properties compared with other ARBs.
Firstly, olmesartan could reduce plasma Ang II levels in hyper-
tensive patients [8–11]. In general, ARBs increase plasma levels
of Ang II due to a lack of negative feedback on renin activity,
which could be harmful in patients with cardiovascular disease.
In contrast, olmesartan, unlike other ARBs, has been reported to
reduce plasma Ang II levels [8–10]. Ichikawa et al. reported that
long-term treatment with olmesartan reduced both blood pressure
and plasma Ang II levels in hypertensive patients [8]. Further-
more, several studies demonstrated that change of an ARB from
candesartan to olmesartan ameliorated left ventricular hypertro-















Trials of ARB in hypertensive Japanese patients.
Trials CASE-J trial HIJ-CREATE study NAGOYA HEART study SUPPORT trial
Objective To compare the long-term effects of
candesartan and amlodipine on the
incidence of cardiovascular events
To test whether ARBs can reduce the
incidence of cardiovascular events
compared with non-ARB-based
standard pharmacotherapy in CAD
patients with hypertension
To examine whether valsartan is
superior to amlodipine to reduce
cardiovascular events in hypertensive
patients with glucose intolerance
To investigate whether an additive
treatment with olmesartan will reduce
the mortality and morbidity in
hypertensive patients with stable
chronic heart failure
Comparison ARB vs. CCB ARB vs. non-ARB ARB vs. CCB ARB vs. Control
Design  PROBE study PROBE study PROBE study PROBE study
Patients  High-risk hypertensive patients
(N = 4728)
CAD patients with hypertension
(N = 2049)
Hypertensive patients with glucose
intolerance (N = 1150)
Hypertensive patients with
symptomatic heart failure (N = 1147)
Endpoints Composite of sudden death and
cerebrovascular, cardiac, renal, and
vascular events
Composite of cardiovascular death,
non-fatal MI,  unstable angina, HF,
stroke, and other cardiovascular events
requiring hospitalization
Composite of MI,  stroke, coronary
revascularization, admission attributed
to  HF, or sudden cardiac death
Composite of all-cause death, non-fatal
MI,  non-fatal stroke and hospital
admission due to worsening
congestive HF
Follow-up 3.2 years (average) 4.2 years (median) 3.2 years (median) At least 3 years
Results No difference (ARB 5.7% vs. CCB 5.7%,
HR: 1.01; 95% CI: 0.79–1.28; P = 0.969)
No difference (ARB 28.1% vs. non-ARB
25.8%, HR: 0.89; 95% CI: 0.76–1.06,
P = 0.19).
No difference (ARB 9.4% vs. CCB 9.7%,
HR  0.97, 95% CI: 0.66–1.40, P = 0.85).
–
Publication Ref. [30] Ref. [31] Ref. [32] –
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he effect of olmesartan to reduce circulating Ang II levels may  be
ssociated with up-regulation of ACE2, an ACE-related carboxypep-
idase that hydrolyzes Ang II to angiotensin 1–7 [Ang-(1–7)] and
ngiotensin I to angiotensin-(1–9). Agata et al. reported that olme-
artan increased ACE2 and prevented an increase in Ang II levels,
uppressing cardiovascular remodeling through increased cardiac
roduction of nitric oxide and endogenous Ang-(1–7) [11]. Since
ng-(1–7) potentiates the effect of bradykinin and acts as an
ndogenous ACE inhibitor, olmesartan may  exert an ACE inhibitory
ction in addition to its blocking action on AT1 receptor.
nverse agonist action of olmesartan
It has been reported that some ARBs act without blocking the
T1 receptor by its inverse agonist action [12,13,29]. In particu-
ar, olmesartan has a potent inverse agonist action through the
ydroxyl group in the imidazole ring together with the carboxyl
roup [7,12,13]. Zou et al. reported that the AT1 receptor in cultured
at cardiomyocytes is activated by mechanical stretch without
nvolvement of Ang II and that this effect was  suppressed by an
nverse agonist action of olmesartan [12]. Thus, olmesartan could
e useful for the treatment of patients with HF, where RAAS in car-
iomyocytes is activated in part in response to mechanical stretch.
ummary
The SUPPORT trial will elucidate whether additive treatment
ith an ARB, olmesartan, reduces the mortality and morbidity of
ypertensive patients with stable HF and may  provide new evi-
ence for ARBs in the management of stable HF in the real world
etting.
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